I think this FTSE 100 dividend stock could double investors’ money

This FTSE 100 company is set to benefit tremendously from global growth, and investors should be well rewarded.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 contains some of the largest companies in the world. As such, there’s a limited number of companies in the index that have the potential to double investors’ money.

Legendary investor Jim Slater even coined a phrase to demonstrate this idea. His famous statement that “elephants don’t gallop” illustrates the view that big corporations rarely double in size, but small ones can.

However, GlaxoSmithKline (LSE: GSK) could be the exception to this rule.

Income and growth

Glaxo has embraced its position as one of the world’s largest pharmaceutical groups over the past few years. The company has doubled down on its research and development spending while selling off or closing down non-core divisions or research initiatives.

The results of this strategy are already starting to show through. City analysts are forecasting a 35% increase in earnings per share this year, on the back of improving revenue growth.

Over the next few years, we should see this trend continue as new treatments flow through the company’s pipeline and make it to market.

At the same time, management has promised to pursue the spin-off of Glaxo’s healthcare business. At the end of 2018, the company reached a landmark agreement with US pharmaceutical giant Pfizer, to combine the two businesses’ consumer health divisions. The deal was closed in August 2019, creating the world’s largest over-the-counter (OTC) business with robust iconic brands.

Analysts have long claimed that the market is undervaluing this part of the business. As such, the City believes that investors could be set for a big payoff when Glaxo splits off this division.

Capital growth potential

Glaxo’s break-up offers capital growth potential. The stock also comes with a dividend yield of 4.5% at the time of writing. The payout is covered 1.5 times by earnings per share, suggesting that it is sustainable for the foreseeable future and could rise substantially from current levels.

Also, shares in the pharmaceutical giant are currently dealing at a price-to-earnings (P/E) ratio of just 14.6. This indicates that the stock offers a wide margin of safety. The rest of the UK pharmaceutical sector is trading at a P/E ratio of more than 17.

Double your money

Glaxo’s dividend yield, coupled with the company’s low valuation and its growth potential over the next few years, signifies that the stock could double investors’ money over the next 10 years.

A dividend yield of 4.5% as well as earnings growth of around 3% per annum — in line with inflation — suggests that shares in Glaxo could yield a return of 7.5% per annum for investors, doubling an investment of £1,000 in 10 years. That’s without taking into account any increase in the company’s valuation or an increase in value from a spin-off of the Pfizer joint venture.

Therefore, now could be the right time to buy a slice of this business to take advantage of its income and growth potential over the next decade.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »